Orthofix is renewing its partnership with MTF Biologics for marketing and development of products.
Under the renewed agreement, Orthofix will continue its exclusive marketing of the Trinity allograft product line through 2023, according to a May 3 news release. Orthofix will also continue working with MTF Biologics on the development of a demineralized bone matrix.
The bone matrix, called the Legacy DBM, will complement Orthofix's demineralized bone line, which includes FiberFuse.
"This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings," Orthofix President of Global Spine Kevin Kenny said in the release. "The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients."